Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IRTC 
iRhythm Technologies Inc (IRTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: IRTC (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
13 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $145.92
1 Year Target Price $145.92
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.46% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.94B USD | Price to earnings Ratio - | 1Y Target Price 145.92 |
Price to earnings Ratio - | 1Y Target Price 145.92 | ||
Volume (30-day avg) 13 | Beta 1.41 | 52 Weeks Range 55.92 - 157.13 | Updated Date 06/30/2025 |
52 Weeks Range 55.92 - 157.13 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.9% | Operating Margin (TTM) -19.49% |
Management Effectiveness
Return on Assets (TTM) -4.37% | Return on Equity (TTM) -111.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5156305826 | Price to Sales(TTM) 7.98 |
Enterprise Value 5156305826 | Price to Sales(TTM) 7.98 | ||
Enterprise Value to Revenue 8.34 | Enterprise Value to EBITDA -34.37 | Shares Outstanding 31925300 | Shares Floating 31540887 |
Shares Outstanding 31925300 | Shares Floating 31540887 | ||
Percent Insiders 1.1 | Percent Institutions 114.96 |
Analyst Ratings
Rating 4 | Target Price 145.92 | Buy 3 | Strong Buy 9 |
Buy 3 | Strong Buy 9 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
iRhythm Technologies Inc
Company Overview
History and Background
iRhythm Technologies, Inc. was founded in 2006. The company is focused on developing and commercializing solutions for cardiac monitoring. Their primary innovation is the Zio XT patch, a wearable ECG monitoring device. They have grown significantly, becoming a key player in long-term ambulatory cardiac monitoring.
Core Business Areas
- Ambulatory Cardiac Monitoring: Provides a comprehensive solution for long-term continuous cardiac monitoring using the Zio platform, which includes a wearable sensor, data analysis, and reporting services.
Leadership and Structure
Quentin Blackford is the CEO. The company operates with functional teams focused on sales, marketing, research and development, operations, and finance.
Top Products and Market Share
Key Offerings
- Zio XT: A wearable patch that continuously records ECG data for up to 14 days. iRhythm holds a significant market share in the long-term ambulatory cardiac monitoring space. Exact market share figures fluctuate, but estimates suggest they hold a leading position. Competitors include Medtronic, Boston Scientific, and Philips. Revenue primarily derived from the Zio XT patch. Number of patients is in millions. This is iRhythms main revenue product.
Market Dynamics
Industry Overview
The ambulatory cardiac monitoring market is growing due to an aging population, increasing prevalence of cardiac arrhythmias, and technological advancements in wearable devices. This includes telehealth growth and remote monitoring.
Positioning
iRhythm is positioned as a leader in long-term continuous ambulatory cardiac monitoring, differentiating itself through its Zio platform, data analytics capabilities, and focus on clinical validation.
Total Addressable Market (TAM)
The estimated total addressable market for ambulatory cardiac monitoring is multi-billion dollars. iRhythm is capturing a significant portion of this, with considerable room for further expansion and geographic growth.
Upturn SWOT Analysis
Strengths
- Innovative Zio platform
- Strong clinical validation
- Established brand recognition
- Proprietary data analytics capabilities
- Strong sales and marketing force
Weaknesses
- Single product dependency (Zio XT)
- Reimbursement challenges related to Medicare and Medicaid approvals
- High operating expenses
- Limited geographic diversification
Opportunities
- Expanding product line (e.g., next-generation monitoring devices)
- Geographic expansion into international markets
- Strategic partnerships with hospitals and healthcare providers
- Integration with telehealth platforms
- Expansion of data analytics capabilities and services
Threats
- Increased competition from established medical device companies
- Changes in reimbursement policies
- Technological advancements by competitors
- Economic downturn affecting healthcare spending
- Product liability lawsuits
Competitors and Market Share
Key Competitors
- MDT
- BSX
- PHIL
Competitive Landscape
iRhythmu2019s advantage lies in its Zio platform and data analytics, but it faces strong competition from larger companies with more diverse product portfolios and extensive distribution networks.
Growth Trajectory and Initiatives
Historical Growth: iRhythm has experienced substantial revenue growth in the past, driven by increased adoption of the Zio XT patch. However, recent growth has been affected by reimbursement challenges.
Future Projections: Analyst projections suggest continued growth in the long term, but with volatility dependent on regulatory and reimbursement factors.
Recent Initiatives: Recent initiatives include efforts to secure broader reimbursement coverage, develop next-generation products, and expand their data analytics offerings.
Summary
iRhythm is a leader in long-term ambulatory cardiac monitoring with a strong product in the Zio XT. Reimbursement challenges remain a concern. The company needs to diversify product offerings and expand geographically. Its data analytics capabilities provide a competitive edge, but it faces stiff competition from larger, established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iRhythm Technologies Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2016-10-20 | President, CEO & Director Mr. Quentin S. Blackford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2000 | Website https://www.irhythmtech.com |
Full time employees 2000 | Website https://www.irhythmtech.com | ||
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.